comparemela.com

Latest Breaking News On - Johannes de munter - Page 2 : comparemela.com

First patient in stem cell trial for treatment of Traumatic Spinal Cord Injury

Neuroplast has enrolled its first patient in a Phase II clinical trial to evaluate efficacy of its transformative Neuro-Cells® treatment that aims to

United statesAgencia espaAntonio olivieroMedicamentosy productos sanitariosNational videnskabsetisk komitDanish medicines agencyTraumatic spinal cord injuryHospital nacional de paraplPrincipal investigators antonio olivieroHospital paraplPrincipal investigatorSpinal cord injurySpinal cordProductos sanitariosDanish medicinesJohannes de munter

Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells treatment for Traumatic Spinal Cord Injury

Neuro-Cells treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following traumaThe randomized, placebo-controlled, international multi-center

United statesNoord hollandKostenloser wertpapierhandelErik woltersPrnewswire neuroplastAntonio olivieroMedicamentosy productos sanitariosBrightlands agrifood fundNational videnskabsetisk komitNetherlands enterprise agencyDanish medicines agencyDutch ministry of economic affairsTraumatic spinal cord injuryTraumatic brain injuryFrontotemporal dementiaHospital nacional de parapl

Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury

Neuro-Cells® treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following trauma The randomized,.

United statesNoord hollandAgencia espaErik woltersPrnewswire neuroplastAntonio olivieroMedicamentosy productos sanitariosBrightlands agrifood fundNational videnskabsetisk komitNetherlands enterprise agencyDanish medicines agencyDutch ministry of economic affairsTraumatic spinal cord injuryTraumatic brain injuryFrontotemporal dementiaHospital nacional de parapl

Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter De Geus to its supervisory board

- Appointments instrumental in the further development of advanced cell-based therapies for inflammation-driven neurological disorders GELEEN, Netherlands, Oct. 21, 2021 /PRNewswire/

Noord hollandGil beyenErik woltersWim brouwerMarcel kloostermanFrank luytenKostenloser wertpapierhandelPrnewswire neuroplastSasja verhoogDutch sanquin health solutionsSanquin health solutionsSanquin foundationPieter de geusManaging directorTraumatic spinal cordBelgian tigenix

vimarsana © 2020. All Rights Reserved.